
| ID | 69137 |
| フルテキストURL | |
| 著者 |
Okubo, So
Department of Neurology, Graduate School of Medicine, The University of Tokyo
Naruse, Hiroya
Department of Neurology, Graduate School of Medicine, The University of Tokyo
Ishiura, Hiroyuki
Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sudo, Atsushi
Department of Neurology, Graduate School of Medicine, The University of Tokyo
Esaki, Kayoko
Department of Biotechnology and Life Sciences, Faculty of Biotechnology and Life Sciences, Sojo University
Mitsui, Jun
Department of Neurology, Graduate School of Medicine, The University of Tokyo
Matsukawa, Takashi
Department of Neurology, Graduate School of Medicine, The University of Tokyo
Satake, Wataru
Department of Neurology, Graduate School of Medicine, The University of Tokyo
Greimel, Peter
Laboratory for Cell Function Dynamics, RIKEN Centre for Brain Sciences
Shingai, Nanoka
Division of Applied Life Science, Graduate School of Engineering, Sojo University
Oya, Yasushi
Department of Neurology, National Center of Neurology and Psychiatry
Yoshikawa, Takeo
Laboratory of Molecular Psychiatry, RIKEN Center for Brain Science
Tsuji, Shoji
Department of Neurology, Graduate School of Medicine, The University of Tokyo
Toda, Tatsushi
Department of Neurology, Graduate School of Medicine, The University of Tokyo
|
| 抄録 | Introduction Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder of the motor system. Pathogenic variants in SPTLC1, encoding a subunit of serine palmitoyltransferase, cause hereditary sensory and autonomic neuropathy type 1 (HSAN1), and have recently been associated with juvenile ALS. SPTLC1 variants associated with ALS cause elevated levels of sphinganines and ceramides. Reports on ALS associated with SPTLC1 remain limited. This study aimed to investigate the frequency of SPTLC1 variants in ALS and relevant clinical characteristics.
Methods We analyzed whole-exome and whole-genome sequence data from 40 probands with familial ALS and 413 patients with sporadic ALS without previously identified causative variants. Reverse transcription polymerase chain reaction (RT-PCR) analysis and droplet digital PCR (ddPCR) were used to assess splicing and mosaicism, respectively. Plasma sphingolipid levels were quantified to analyze biochemical consequences. Results The heterozygous c.58G>A, p.Ala20Thr variant was identified in a 21-year-old Japanese female patient presenting with symmetric weakness which slowly progressed over 15 years. RT-PCR analysis showed no splice defects. Plasma sphingolipid levels in the patient were significantly increased compared to her asymptomatic parents. ddPCR revealed that the asymptomatic father harbored a mosaic variant with 17% relative mutant allele abundance in peripheral blood leukocytes. Conclusions We identified a pathogenic c.58G>A, p.Ala20Thr SPTLC1 variant in a patient with juvenile ALS, likely inherited from an asymptomatic parent with mosaicism. Lipid analysis results are consistent with previous findings on SPTLC1-associated ALS. Further studies are necessary to determine the clinical effect of mosaic variants of SPTLC1. |
| キーワード | Juvenile amyotrophic lateral sclerosis
SPTLC1
Sphingolipids
Mosaicism
|
| 備考 | The version of record of this article, first published in Journal of Neurology, is available online at Publisher’s website: http://dx.doi.org/10.1007/s00415-024-12776-5
|
| 発行日 | 2024-12-12
|
| 出版物タイトル |
Journal of Neurology
|
| 巻 | 272巻
|
| 号 | 1号
|
| 出版者 | Springer Science and Business Media LLC
|
| 開始ページ | 36
|
| ISSN | 0340-5354
|
| NCID | AA00703276
|
| 資料タイプ |
学術雑誌論文
|
| 言語 |
英語
|
| OAI-PMH Set |
岡山大学
|
| 著作権者 | © The Author(s) 2024
|
| 論文のバージョン | publisher
|
| PubMed ID | |
| DOI | |
| Web of Science KeyUT | |
| 関連URL | isVersionOf https://doi.org/10.1007/s00415-024-12776-5
|
| ライセンス | http://creativecommons.org/licenses/by/4.0/
|
| Citation | Okubo, S., Naruse, H., Ishiura, H. et al. Genetic and functional analyses of SPTLC1 in juvenile amyotrophic lateral sclerosis. J Neurol 272, 36 (2025). https://doi.org/10.1007/s00415-024-12776-5
|
| 助成情報 |
( 東京大学 / University of Tokyo )
JPMH23FC1008:
( 厚生労働省 / Ministry of Health )
23ek0109673:
神経難病の早期特定を実現する革新的ゲノム解析研究
( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )
23ek0109617:
難病のゲノム医療実現に向けた全ゲノム解析の実施基盤の構築と実践
( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )
23ek0109631:
遺伝子治療時代のALS治験即応型レジストリ整備とサロゲートマーカーの探索
( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )
24K18698:
若年発症のALSのゲノム基盤と病態の解明
( 独立行政法人日本学術振興会 / Japan Society for the Promotion of Science )
23K27514:
最先端ゲノム解析技術を用いた神経筋変性疾患の病態解明・治療法開発研究
( 独立行政法人日本学術振興会 / Japan Society for the Promotion of Science )
21K07512:
精神疾患様行動異常へのスフィンゴ脂質シグナル経路の関与の解明
( 独立行政法人日本学術振興会 / Japan Society for the Promotion of Science )
( 理化学研究所 / RIKEN )
|